Companies aim to combine blood-based circRNA biomarkers of disease biology and pathology with objective digital measures of cognition and function, to accelerate Alzheimer’s drug development today and create a scalable frontline care tomorrow. SAN DIEGO and WASHINGTON, Sept. 22, 2026…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
